City Architecture as the Production of Urban Culture: Semiotics Review for Cultural Studies

This article aims to describe correlation between city\u27s architecture as urban culture and cultural studies, specifically in semiotics. This article starts from Chris Barker\u27s statement about city and urban as text in his phenomenal book, Cultural Studies, Theory and Practice. City as a complex subject has been transformed as the representation of urban culture. In the post-modernism view, urban culture as cultural space and cultural studies\u27 sites have significantly pointed to became communications discourse and also part of the identity of Semiology. This article uses semiotics of Saussure for the research methods. Surabaya and Jakarta has been chosen for the objects of this article. The result of this article is describing the significant view of architecture science helps the semiotics in cultural studies. In other way, city\u27s architecture becomes the strong identity of urban culture in Jakarta and Surabaya. Architecture approaches the cultural studies to view urban culture, especially in symbol and identity in the post-modernism era

Variasi Kuat Kokoh Tanah Lempung Ekspansif Akibat Perubahan Musim

Tanah lempung ekspansif yang tidak diperhitungkan dengan baik dapat mengakibatkan kerusakan pada struktur bangunan. Wetting dan drying, merupakan sebuah metode yang digunakan untuk mengetahui kondisi tanah pada saat musim hujan dan kemarau. Proses wetting dilakukan dengan cara tanah dibasahi untuk mencari beratnya sedangkan drying dilakukan dengan cara tanah dikeringkan pada ruangan tertutup untuk mencari beratnya. Tujuan dari penelitian ini adalah mengetahui pengaruh indeks plastisitas dan persentase fine aggregate terhadap Perubahan kuat kokoh akibat wetting dan drying. Karakteristik tanah pada kondisi mula-mula dari lima lokasi di Surabaya Barat didapatkan dari pengujian di laboratorium UK Petra. Pada saat proses wetting, tanah dibasahi sampai berat tanah yang diinginkan, sedangkan pada proses drying tanah dibiarkan di ruangan sampai mencapai berat tanah yang diinginkan. Hasil dari penelitian ini menunjukkan bahwa nilai indeks plastisitas yang semakin tinggi mengakibatkan range kuat kokoh yang kecil, dan persentase fine aggregate yang semakin tinggi mengakibatkan range kuat kokoh yang besar

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

BACKGROUND: Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG) to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, specific therapy for an outbreak infection such as SARS-CoV-2. Findings from randomised clinical trials of hIVIG for the treatment of COVID-19 are limited. METHODS: In this international randomised, double-blind, placebo-controlled trial, hospitalised patients with COVID-19 who had been symptomatic for up to 12 days and did not have acute end-organ failure were randomly assigned (1:1) to receive either hIVIG or an equivalent volume of saline as placebo, in addition to remdesivir, when not contraindicated, and other standard clinical care. Randomisation was stratified by site pharmacy; schedules were prepared using a mass-weighted urn design. Infusions were prepared and masked by trial pharmacists; all other investigators, research staff, and trial participants were masked to group allocation. Follow-up was for 28 days. The primary outcome was measured at day 7 by a seven-category ordinal endpoint that considered pulmonary status and extrapulmonary complications and ranged from no limiting symptoms to death. Deaths and adverse events, including organ failure and serious infections, were used to define composite safety outcomes at days 7 and 28. Prespecified subgroup analyses were carried out for efficacy and safety outcomes by duration of symptoms, the presence of anti-spike neutralising antibodies, and other baseline factors. Analyses were done on a modified intention-to-treat (mITT) population, which included all randomly assigned participants who met eligibility criteria and received all or part of the assigned study product infusion. This study is registered with ClinicalTrials.gov, NCT04546581. FINDINGS: From Oct 8, 2020, to Feb 10, 2021, 593 participants (n=301 hIVIG, n=292 placebo) were enrolled at 63 sites in 11 countries; 579 patients were included in the mITT analysis. Compared with placebo, the hIVIG group did not have significantly greater odds of a more favourable outcome at day 7; the adjusted OR was 1·06 (95% CI 0·77–1·45; p=0·72). Infusions were well tolerated, although infusion reactions were more common in the hIVIG group (18·6% vs 9·5% for placebo; p=0·002). The percentage with the composite safety outcome at day 7 was similar for the hIVIG (24%) and placebo groups (25%; OR 0·98, 95% CI 0·66–1·46; p=0·91). The ORs for the day 7 ordinal outcome did not vary for subgroups considered, but there was evidence of heterogeneity of the treatment effect for the day 7 composite safety outcome: risk was greater for hIVIG compared with placebo for patients who were antibody positive (OR 2·21, 95% CI 1·14–4·29); for patients who were antibody negative, the OR was 0·51 (0·29–0·90; pinteraction=0·001). INTERPRETATION: When administered with standard of care including remdesivir, SARS-CoV-2 hIVIG did not demonstrate efficacy among patients hospitalised with COVID-19 without end-organ failure. The safety of hIVIG might vary by the presence of endogenous neutralising antibodies at entry. FUNDING: US National Institutes of Health

Implementation of the Apostle Paul's Teaching Based on Romans 12:6 – 8 to the Christian Teachers

In Romans 12:6 -8 the Apostle Paul's teaching to the Christian teachers to give the totality of life. Because by giving this totality of life, he can be an inspiration and a strategic figure radiating the Real picture of Christ for his students. But the reality in the field is that there are still Christian teachers who have not shown the totality of their lives for God. There are Christian teachers who are often late, and even less serious in carrying out their teaching duties. This indicates that the teacher has not implemented the Apostle Paul's teaching  based on Romans 12:6-8. The first advice of the Apostle Paul in Romans 12:1-2 emphasizes that Christians must offer their lives as true worship, namely by offering his work as a living body offering by being a professional teacher like Christ, but from the results of surveys and interviews, it is known that there are still Christian teachers who still teach less seriously just to seek fulfillment of 24 hours face-to-face as a minimum teacher hour requirement. This indicates that the teacher has not implemented to Paul's teaching  based on Romans 12:6-

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.

BACKGROUND: Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG) to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, specific therapy for an outbreak infection such as SARS-CoV-2. Findings from randomised clinical trials of hIVIG for the treatment of COVID-19 are limited. METHODS: In this international randomised, double-blind, placebo-controlled trial, hospitalised patients with COVID-19 who had been symptomatic for up to 12 days and did not have acute end-organ failure were randomly assigned (1:1) to receive either hIVIG or an equivalent volume of saline as placebo, in addition to remdesivir, when not contraindicated, and other standard clinical care. Randomisation was stratified by site pharmacy; schedules were prepared using a mass-weighted urn design. Infusions were prepared and masked by trial pharmacists; all other investigators, research staff, and trial participants were masked to group allocation. Follow-up was for 28 days. The primary outcome was measured at day 7 by a seven-category ordinal endpoint that considered pulmonary status and extrapulmonary complications and ranged from no limiting symptoms to death. Deaths and adverse events, including organ failure and serious infections, were used to define composite safety outcomes at days 7 and 28. Prespecified subgroup analyses were carried out for efficacy and safety outcomes by duration of symptoms, the presence of anti-spike neutralising antibodies, and other baseline factors. Analyses were done on a modified intention-to-treat (mITT) population, which included all randomly assigned participants who met eligibility criteria and received all or part of the assigned study product infusion. This study is registered with ClinicalTrials.gov, NCT04546581. FINDINGS: From Oct 8, 2020, to Feb 10, 2021, 593 participants (n=301 hIVIG, n=292 placebo) were enrolled at 63 sites in 11 countries; 579 patients were included in the mITT analysis. Compared with placebo, the hIVIG group did not have significantly greater odds of a more favourable outcome at day 7; the adjusted OR was 1·06 (95% CI 0·77-1·45; p=0·72). Infusions were well tolerated, although infusion reactions were more common in the hIVIG group (18·6% vs 9·5% for placebo; p=0·002). The percentage with the composite safety outcome at day 7 was similar for the hIVIG (24%) and placebo groups (25%; OR 0·98, 95% CI 0·66-1·46; p=0·91). The ORs for the day 7 ordinal outcome did not vary for subgroups considered, but there was evidence of heterogeneity of the treatment effect for the day 7 composite safety outcome: risk was greater for hIVIG compared with placebo for patients who were antibody positive (OR 2·21, 95% CI 1·14-4·29); for patients who were antibody negative, the OR was 0·51 (0·29-0·90; pinteraction=0·001). INTERPRETATION: When administered with standard of care including remdesivir, SARS-CoV-2 hIVIG did not demonstrate efficacy among patients hospitalised with COVID-19 without end-organ failure. The safety of hIVIG might vary by the presence of endogenous neutralising antibodies at entry. FUNDING: US National Institutes of Health